The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer indication, but biological complexity may limit this approach.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Cancer Cell International Open Access 12 November 2022
-
The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology
Virchows Archiv Open Access 02 March 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov 17, 227–229 (2018). https://doi.org/10.1038/nrd.2018.6
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.6
This article is cited by
-
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Cancer Cell International (2022)
-
The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology
Virchows Archiv (2020)
-
Tumor-Agnostic Treatment for Cancer: When How is Better than Where
Clinical Drug Investigation (2020)
-
FDA approves landmark tissue-agnostic cancer drug
Nature Reviews Drug Discovery (2019)
-
Public biotech in 2017—the numbers
Nature Biotechnology (2018)